The long-term persistence of tumor necrosis factor inhibitors in patients with moderate to severe immune-mediated rheumatic diseases: A nation-wide, population-based real-world study.
Jing-Yang HuangPui-Ying LeongAmy KerHsin-Hua ChenJames Cheng-Chung WeiPublished in: International journal of rheumatic diseases (2022)
Golimumab had better drug survival than etanercept or adalimumab over 5 years of observation in Asian IMRD patients. Gender, age, longer hospital stays, concomitant use of disease-modifying antirheumatic drugs were associated with survival with TNFis.
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- ankylosing spondylitis
- newly diagnosed
- ejection fraction
- chronic kidney disease
- juvenile idiopathic arthritis
- rheumatoid arthritis patients
- peritoneal dialysis
- healthcare
- prognostic factors
- adverse drug
- disease activity
- drug induced
- early onset
- emergency department
- systemic lupus erythematosus
- electronic health record